Amarin Corporation PLC
First Floor, Block 3
The Oval<br>Shelbourne Road
Ballsbridge
Dublin
W1J 5HG
Tel: 353-01-6699020
Fax: 353-01-6699028
Website: http://www.amarincorp.com/
Email: rick.stewart@amarincorp.com
308 articles with Amarin Corporation PLC
-
“With this drug, we are not only preventing that first heart attack, but potentially the second stroke and maybe that third fatal event,” stated Deepak Bhatt, the study’s lead investigator.
-
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm
3/15/2019
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
-
On day two of Cowen and Company’s 39th Annual Health Care Conference, more companies shared insight into pipeline development. BioSpace rounded up a few of the stories.
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amarin Corporation plc - AMRN
2/26/2019
Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc.
-
Alexander (Sasha) Opotowsky, associate professor at Harvard Medical School and a cardiologist at Boston Children’s Hospital and Brigham and Women’s Hospital took time out to speak with BioSpace about advances in heart health, congenital heart disease (CHD), biopharma, and the Adult Congenital Hea...
-
With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amarin Corporation - AMRN
11/13/2018
Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
-
Clinical data for a fish-oil-based drug from Amarin Corporation PLC confirmed the drug’s ability to reduce the relative risk reduction of adverse cardiovascular events by 25 percent, including a 20 percent reduction in cardiovascular death.
-
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event
11/11/2018
Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes
-
Physicians have long recommended fish oil to patients with high cholesterol and triglycerides, even though the scientific studies on it are mixed. Amarin developed a drug called Vascepa, which derives from a purified component of fish oil called eicosapentaenoic acid (EPA).
-
As we move into the last quarter of 2018, plenty of companies are looking at potential catalysts. George Budwell, writing for The Motley Fool, takes a look at three potentially high-reward biotech companies, but along with their big catalysts comes high risk.
-
Amarin Prices Public Offering of American Depositary Shares
1/30/2018
In addition, Amarin has granted the underwriter a 30-day option to purchase approximately $10.5 million of additional ADSs.
-
Amarin Announces Proposed Public Offering of American Depositary Shares
1/30/2018
On January 26, 2018, the last sale price of the ADSs on The NASDAQ Global Market was $4.27 per share.
-
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events
1/23/2018
Patients are being scheduled for final study visits commencing March 1, 2018. Amarin maintains its guidance to report top-line results from the study before the end of Q3 2018. -
Amarin Announces Commencement of VASCEPA Clinical Development in Mainland China
1/17/2018
Under the parties' February 2015 agreement, Eddingpharm is responsible for Vascepa development, regulatory activities, commercialization and associated costs, including managing and funding this pivotal registration study.
-
Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook
1/5/2018
Amarin plans to discuss these results and expectations with investors in connection with the 36th Annual J.P. Morgan Healthcare Conference.
-
Amarin: Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk
11/15/2017
This analysis of RWE is separate from and independent of the RWE analysis referenced in Amarin’s press release on November 12, 2017.
-
Amarin: Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease
11/14/2017
This oral presentation was held at the American Heart Association (AHA) 2017 Scientific Sessions in Anaheim, California.
-
Amarin Corporation: Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs
11/13/2017
The analysis was presented at the 2017 American Heart Association (AHA) Scientific Sessions in Anaheim, CA.
-
Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations
11/1/2017
Net product revenue in the third quarter of 2017 achieved record levels.